Monoclonal Antibodies are also known as targeted therapies because they work by targeting specific proteins on the surface of the cells. Mabs agents are currently have been successfully used in the treatment of cancers, tumors and other serious diseases and is big on the market.
The market size of Monoclonal antibody agents in 2009-2012 grew at a CAGR of 13% and is expected to rise by more than 12% in 2013-2017 reaching $141 billion in 2017. This is due to great market demand, new products being approved and also launching of Mabs generic drugs.
The global industry of Mabs is currently dominated by European and American companies, however, sales of Mabs in the rest of the world will remain higher than in the U.S despite a higher CAGR in the U.S.
By Attending this conference you will:
Gain insight on various therapeutic targets
Learn the latest and most recent advances in antibody technology
Find out what is the future in antibody technology
Understanding about new antibody engineering and modification technologies
Explore up to date platform approaches to monoclonal antibody purification
Learn new techniques in cell engineering for Mabs production
Examine antibody-based targeted therapy
Study the latest trends in capacity utilization for therapeutic mabs production
Investigate immunogenicity issues with drug development
Hear about latest regulations, technologies, production and therapeutics
Who should attend:
VP’s, Directors, Heads and Managers of:
Preclinical research development
Clinical Research development
Cell and Molecular Biology
Recombitant DNA Biotechnology
Pharmaceutical and Patent Law
Contract research Organizations
New product development